Lidamycin induces apoptosis of human gastric carcinoma BGC823 cells and inhibits xenograft growth in nude mice.
- Author:
Sheng-Hua ZHANG
1
;
Jing CHEN
;
Ming JIANG
;
Yong-Su ZHEN
Author Information
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Aminoglycosides;
pharmacology;
Animals;
Antibiotics, Antineoplastic;
pharmacology;
Apoptosis;
drug effects;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Dose-Response Relationship, Drug;
Enediynes;
pharmacology;
Female;
Humans;
Mice;
Mice, Inbred BALB C;
Mice, Nude;
Neoplasm Transplantation;
Random Allocation;
Stomach Neoplasms;
metabolism;
pathology;
Vascular Endothelial Growth Factor A;
metabolism;
Xenograft Model Antitumor Assays
- From:
Acta Pharmaceutica Sinica
2008;43(6):601-604
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the effect of lidamycin (LDM) on human gastric carcinoma BGC823 cells and xenograft growth in nude mice, MTT (methyl thiazolyl tetrazolium) assay was used to determine the inhibition of BGC823 cell proliferation by LDM. Induction of apoptosis was studied by flow cytometry and TUNEL assay. The expression of VEGF was detected by Western blotting analysis. Athymic nude mice were used to determine in vivo antitumor activity. Proliferation inhibition and apoptosis induction were studied in lidamycin-treated cells. The expression of VEGF in BGC823 cells decreased in a dose-dependent manner. LDM at 0.02 mg x kg(-1) and 0.04 mg x kg(-1) suppressed the growth of BGC823 xenografts in nude mice by 57% and 72%, respectively. LDM potently induces apoptosis in human gastric carcinoma BGC823 cells and inhibits xenograft growth.
